- Home
- Results news
- TTK Healthcare
- Q2 FY27 results
TTK Healthcare Q2 FY27 results: net profit ₹222.97 crore vs ₹20.39 crore, revenue up 14.6%
TTK Healthcare Limited reported standalone Q2 FY27 revenue of ₹233.38 crore, up 14.6% from the year-ago quarter but down 9.4% from Q1 FY27. A ₹248.20 crore exceptional gain lifted net profit to ₹222.97 crore and basic EPS to ₹157.80, while EBITDA fell to ₹3.75 crore and its margin narrowed to 1.6%.
Key points
- Revenue was ₹233.38 crore in Q2 FY27, up ₹29.81 crore or 14.6% from Q2 FY26 but down ₹24.18 crore or 9.4% from Q1 FY27.
- A net exceptional gain of ₹248.20 crore helped profit before tax reach ₹267.94 crore, up ₹246.64 crore or 1157.9% from the year-ago quarter.
- Net profit was ₹222.97 crore and basic EPS was ₹157.80, compared with ₹20.39 crore and ₹14.43 in Q2 FY26.
- EBITDA fell 29.6% to ₹3.75 crore from Q2 FY26, while the EBITDA margin declined 1.0 percentage point to 1.6%.
- In H1 FY27, revenue rose 14.2% to ₹490.94 crore and net profit rose 631.5% to ₹244.25 crore.
How did TTK Healthcare perform in Q2 FY27?
TTK Healthcare reported standalone revenue of ₹233.38 crore for Q2 FY27, up 14.6% from ₹203.57 crore in Q2 FY26 but down 9.4% from ₹257.56 crore in Q1 FY27. EBITDA was ₹3.75 crore, down 29.6% from ₹5.33 crore a year earlier and 74.6% from ₹14.74 crore in the previous quarter. The EBITDA margin fell to 1.6% from 2.6% and 5.7%, respectively.
Profit before tax rose to ₹267.94 crore from ₹21.30 crore in Q2 FY26 and ₹28.86 crore in Q1 FY27, reflecting the exceptional gain recorded during the quarter. Net profit was ₹222.97 crore, against ₹20.39 crore in the year-ago quarter and ₹21.28 crore in the previous quarter. Basic EPS was ₹157.80, compared with ₹14.43 and ₹15.06. These figures are standalone; the filing states that TTK Healthcare had no subsidiary, associate or joint venture as of 30 September 2026.
Total income was ₹252.12 crore in Q2 FY27, up ₹29.54 crore or 13.3% from Q2 FY26 but down ₹22.23 crore or 8.1% from Q1 FY27. The company’s filing states that the quarter’s ₹248.20 crore exceptional gain came from the completed sale of its “EVA” and “GoodHome” brands and related assets to Wipro Enterprises Private Limited. The board approved the unaudited results on 30 October 2026.
| ₹ crore | Q2 FY27 | Q1 FY27 | Q2 FY26 | YoY | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 233.38 | 257.56 | 203.57 | +14.6% | −9.4% |
| Other income | 18.74 | 16.79 | 19.01 | −1.4% | +11.6% |
| Total expenses | 232.39 | 245.49 | 201.28 | +15.5% | −5.3% |
| EBITDA | 3.75 | 14.74 | 5.33 | −29.6% | −74.6% |
| EBITDA margin | 1.6% | 5.7% | 2.6% | −1.0 pp | −4.1 pp |
| Profit before tax | 267.94 | 28.86 | 21.30 | +1157.9% | +828.4% |
| Tax | 44.96 | 7.58 | 0.91 | +4840.7% | +493.1% |
| Net profit | 222.97 | 21.28 | 20.39 | +993.5% | +947.8% |
| EPS (₹) | 157.80 | 15.06 | 14.43 | +993.6% | +947.8% |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What changed in TTK Healthcare's costs and profit?
Total expenses were ₹232.39 crore in Q2 FY27, up ₹31.11 crore or 15.5% from ₹201.28 crore in Q2 FY26 but down ₹13.10 crore or 5.3% from Q1 FY27. Cost of materials consumed increased ₹19.39 crore or 40.4% to ₹67.44 crore, and other expenses rose ₹10.27 crore or 17.3% to ₹69.54 crore. Employee cost increased ₹5.27 crore or 12.8% to ₹46.38 crore, while finance costs fell ₹0.25 crore or 29.8% to ₹0.59 crore and depreciation fell ₹0.05 crore or 2.3% to ₹2.16 crore.
Other income was ₹18.74 crore, down ₹0.27 crore or 1.4% from ₹19.01 crore in Q2 FY26 and up ₹1.95 crore or 11.6% from ₹16.79 crore in Q1 FY27. The quarter included a ₹248.20 crore net exceptional gain, compared with no exceptional item in Q2 FY26 and Q1 FY27. Tax expense was ₹44.96 crore, up ₹44.05 crore from ₹0.91 crore a year earlier and up ₹37.38 crore from ₹7.58 crore in the previous quarter.
| ₹ crore | Q2 FY27 | Q2 FY26 | Change | Change % |
|---|---|---|---|---|
| Cost of materials | 67.44 | 48.05 | +19.39 | +40.4% |
| Employee cost | 46.38 | 41.11 | +5.27 | +12.8% |
| Finance costs | 0.59 | 0.84 | −0.25 | −29.8% |
| Depreciation | 2.16 | 2.21 | −0.05 | −2.3% |
| Other expenses | 69.54 | 59.27 | +10.27 | +17.3% |
| Total expenses | 232.39 | 201.28 | +31.11 | +15.5% |
| Other income | 18.74 | 19.01 | −0.27 | −1.4% |
| Tax | 44.96 | 0.91 | +44.05 | +4840.7% |
| Exceptional items | +248.20 (gain) | none |
Source: Company's results filing (XBRL).
How did the first half of FY27 go?
In the first half of FY27, TTK Healthcare reported standalone revenue of ₹490.94 crore, up 14.2% from ₹430.0 crore in H1 FY26. Total income rose 12.7% to ₹526.48 crore from ₹466.95 crore, while profit before tax increased from ₹38.95 crore to ₹296.79 crore and net profit rose 631.5% to ₹244.25 crore from ₹33.39 crore. Basic EPS was ₹172.86, compared with ₹23.63 in the year-ago period.
| ₹ crore | H1 FY27 | H1 FY26 | Change |
|---|---|---|---|
| Revenue from operations | 490.94 | 430 | +14.2% |
| Profit before tax | 296.79 | 38.95 | +662.0% |
| Net profit | 244.25 | 33.39 | +631.5% |
| EPS (₹) | 172.86 | 23.63 | +631.5% |
Source: Company's results filing (XBRL).
What do the balance sheet and cash flow show?
At 30 September 2026, total assets were ₹1,651.24 crore, up from ₹1,328.74 crore at 31 March 2026, while total equity rose to ₹1,346.54 crore from ₹1,114.85 crore. Borrowings were ₹25.96 crore, compared with ₹23.88 crore, and cash and cash equivalents increased to ₹89.84 crore from ₹21.88 crore. Inventories were ₹112.94 crore against ₹108.72 crore, trade receivables ₹117.05 crore against ₹110.66 crore, and trade payables ₹117.77 crore against ₹91.3 crore.
H1 FY27 operating cash flow was ₹50.22 crore, compared with an outflow of ₹22.55 crore in H1 FY26. Investing cash flow was ₹29.42 crore, compared with ₹39.75 crore, and financing cash flow was an outflow of ₹11.68 crore against an outflow of ₹13.51 crore. Capital expenditure was ₹11.79 crore, compared with ₹2.89 crore in the year-ago period.
| ₹ crore | As of 30 September 2026 | As of 31 March 2026 |
|---|---|---|
| Total assets | 1,651 | 1,329 |
| Total equity | 1,347 | 1,115 |
| Borrowings | 25.96 | 23.88 |
| Cash and equivalents | 89.84 | 21.88 |
| Inventories | 112.94 | 108.72 |
| Trade receivables | 117.05 | 110.66 |
Source: Company's results filing (XBRL).
| ₹ crore | H1 FY27 | H1 FY26 |
|---|---|---|
| Cash from operations | 50.22 | −22.55 |
| Cash from investing | 29.42 | 39.75 |
| Cash from financing | −11.68 | −13.51 |
| Capital expenditure | 11.79 | 2.89 |
Source: Company's results filing (XBRL).
How has TTK Healthcare done over the last 8 quarters?
Revenue rose year on year in each of the last eight quarters, according to the reported sequence. It reached its latest peak of ₹257.56 crore in Q1 FY27 before falling to ₹233.38 crore in Q2 FY27; the earlier low in the period shown was ₹190.36 crore in Q4 FY25. Revenue had reached ₹217.98 crore in Q4 FY26 before rising in the following quarter.
Net profit peaked at ₹222.97 crore in Q2 FY27, compared with a low of ₹10.53 crore in Q3 FY26, and had risen year on year in each of the last three quarters. EBITDA margin moved in the opposite direction at the latest result, falling from 5.7% in Q1 FY27 to 1.6% in Q2 FY27. The earlier margin low was 1.2% in Q1 FY26, while the high in the period was 6.3% in Q4 FY25.
Which businesses drove the quarter?
Protective Devices reported Q2 FY27 revenue of ₹65.57 crore, up 34.3% from ₹48.83 crore in Q2 FY26, but recorded an EBIT loss of ₹0.76 crore compared with a loss of ₹10.25 crore. Its EBIT margin was -1.2%. Consumer Products revenue was ₹54.56 crore, down 3.0% from ₹56.27 crore, while EBIT moved from ₹9.55 crore to a loss of ₹0.41 crore.
Animal Welfare revenue was ₹41.21 crore, up 16.2% from ₹35.47 crore, with EBIT of ₹2.86 crore compared with ₹3.17 crore and an EBIT margin of 6.9%. Medical Devices revenue rose 14.7% to ₹29.34 crore from ₹25.57 crore, while EBIT fell to ₹5.01 crore from ₹6.06 crore; its EBIT margin was 17.1%.
Foods revenue rose 14.2% to ₹42.62 crore from ₹37.33 crore, and EBIT increased to ₹4.52 crore from ₹3.80 crore, with an EBIT margin of 10.6%. Others recorded revenue of ₹0.08 crore and EBIT of ₹0.09 crore, against ₹0.1 crore and ₹0.11 crore, respectively.
| Segment | Revenue | Revenue YoY | EBIT | EBIT margin |
|---|---|---|---|---|
| ANIMAL WELFARE | 41.21 | +16.2% | 2.86 | 6.9% |
| CONSUMER PRODUCTS | 54.56 | −3.0% | −0.41 | -0.7% |
| MEDICAL DEVICES | 29.34 | +14.7% | 5.01 | 17.1% |
| PROTECTIVE DEVICES | 65.57 | +34.3% | −0.76 | -1.2% |
| FOODS | 42.62 | +14.2% | 4.52 | 10.6% |
| OTHERS | 0.08 | −22.7% | 0.09 | 110.8% |
Source: Company's results filing (XBRL segment data).
How did TTK Healthcare shares react?
The stock moved from a pre-results close of ₹1,049.0 to ₹1,043.4 when the filing appeared, a decline of 1.5%. It was down 2.4% after 15 minutes and 2.7% after 30 minutes. On the reaction day, it fell 14.0%; by the next day’s close, the decline from the same pre-results close was 12.7%.
The Diversified industry median fell 1.3% on the reaction day and 0.4% by the next day’s close. TTK Healthcare therefore underperformed the industry median by 12.8 percentage points on the reaction day and 12.3 percentage points by the next day’s close. The Nifty Microcap 250 fell 2.5% and 1.1%, respectively, over the same closes.
Earlier results-day reactions were mixed: the shares rose 3.8% on 6 August 2026 and 30 May 2026, fell 2.1% on 22 January 2026, rose 2.6% on 17 October 2025, fell 3.4% on 4 August 2025, and rose 1.6% on both 23 May 2025 and 24 January 2025. No five-day reaction was provided for the latest result.
| After the filing | Stock | Diversified median |
|---|---|---|
| 5 minutes | −1.5% | |
| 15 minutes | −2.4% | |
| 30 minutes | −2.7% | |
| Reaction day | −14.0% | −1.3% |
| Next day | −12.7% | −0.4% |
Minutes are measured from the price when the filing appeared; days from the previous close. Source: MarketPing price-reaction measurement.
| Results filed on | Stock on the reaction day |
|---|---|
| 6 August 2026 | +3.8% |
| 30 May 2026 | +3.8% |
| 22 January 2026 | −2.1% |
| 17 October 2025 | +2.6% |
| 4 August 2025 | −3.4% |
| 23 May 2025 | +1.6% |
| 24 January 2025 | +1.6% |
| 25 October 2024 | +1.3% |
Source: MarketPing price-reaction measurement.
Quick answers
What was TTK Healthcare's revenue in Q2 FY27?
Revenue from operations was ₹233.38 crore, up 14.6% from ₹203.57 crore in Q2 FY26 (standalone).
Did TTK Healthcare make a profit in Q2 FY27?
Yes. Net profit was ₹222.97 crore, against a net profit of ₹20.39 crore in Q2 FY26.
What was TTK Healthcare's EPS in Q2 FY27?
Basic earnings per share were ₹157.80, against ₹14.43 in Q2 FY26.
How did TTK Healthcare shares react to the Q2 FY27 results?
On the reaction day the stock moved −14.0% from the previous close; the median Diversified stock moved −1.3%.
When did TTK Healthcare announce its Q2 FY27 results?
On 30 October 2026, in a filing to the BSE.
Sources
- Board Meeting Intimation for Board Meeting To Be Held On October 30, 2026. (BSE, 23 October 2026) · PDF
- Board Meeting Outcome for Outcome Of Board Meeting (BSE, 30 October 2026) · PDF
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.